While extensive CVOTs have established that GLP-1 RAs reduce the risk of MACEsin patients with T2D [52], specific data on dual GLP-1/Gcg RAs, such ascotadutide and survodutide, are currently limited. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.